CPC: Chemical distributor with modest margins, accounting red flags and limited upside
Intrinsic value VND 14,850 vs market price VND 15,500 — implied downside of -4.2% (model confidence: very_low).
Business Overview
Công ty Cổ phần Thuốc sát trùng Cần Thơ (CPC) is a HNX-listed chemical company operating in the Hóa chất subsector. The firm sells disinfectants and agricultural/chemical products and is a small-cap issuer with 4,081,450 shares outstanding. Revenue has contracted from VND 190.0 bn in 2024 to VND 171.3 bn in 2025, reflecting near-term cyclicality in demand.
CPC reports moderate gross margins (23.1%) and thin net margins (5.3%). Its balance sheet shows modest leverage — Debt/Equity of 0.567 — and an Altman Z-Score (reported in forensic positives) that suggests low bankruptcy risk. Ownership is concentrated: one institutional holder at 20.33% and several insiders (13.36%, 8.37%, 5.03%, 4.69%), limiting free float and contributing to illiquidity.
Investment Thesis
CPC's valuation is not compelling on the basis of upside: our EV/EBITDA mid-cycle model implies an intrinsic value of VND 14,850 versus a market price of VND 15,500, implying a -4.2% downside. The model uses a mid-cycle EV/EBITDA multiple of 4.27 (own history) applied to a mid-cycle EBITDA of about VND 14.5 bn and net debt of roughly VND 15.9 bn; sector EV/EBITDA is materially higher at 9.14, but CPC's historical multiple and earnings volatility justify a discount.
Fundamentally, CPC generates positive profits (net profit VND 9.0 bn in 2025; EPS VND 2,214) and returns (ROE 10.5%, ROA 7.0%). Valuation metrics look cheap superficially: P/E 7.4 and P/B 0.8, and a high reported dividend yield of 9.7%. However, earnings quality concerns (score 7.9/100) and forensic red flags materially reduce confidence in reported profits and cash conversion. Receivables and cash conversion scores are reported as 0/100, which undermines the investment case based solely on low multiples.
Operationally, revenue has declined (Revenue YoY -9.9%) and EBITDA volatility is non-trivial (EBITDA CV 0.1679). With limited liquidity (average daily volume ~367 shares over two weeks) and concentrated ownership, price moves can be idiosyncratic. Given the model's very_low confidence and forensic risks, the implied downside is too narrow to offset execution and accounting risks.
Valuation Commentary
EV/EBITDA mid-cycle: apply a calibrated mid-cycle EV/EBITDA multiple to a mid-cycle EBITDA and back out per-share intrinsic value after adjusting for net debt and shares outstanding.
- Mid-cycle EBITDA of approximately VND 14.5 bn (model input: 14,542,424,431).
- Fair EV/EBITDA of 4.27 derived from the companys own history (sector median EV/EBITDA = 9.14).
- Net debt of roughly VND 15.9 bn deducted from enterprise value.
- Calibration (isotonic) adjusted raw intrinsic per-share value (raw_intrinsic_value VND 11,303) to final intrinsic value VND 14,850; model trained on 7 years of data and shows EBITDA CV 0.1679.
- Model confidence flagged as very_low and sanity_flags include illiquid, low_earnings_quality, manipulation_risk.
The model produces an intrinsic value slightly below the current price, implying limited downside (-4.2%) but the confidence is very low due to weak earnings quality and liquidity issues. The large spread between CPCs fair EV/EBITDA (4.27) and sector EV/EBITDA (9.14) explains much of the discount; given forensic flags, we have low conviction in the stated accounting inputs and therefore in the intrinsic estimate.
Bull vs Bear
- Cheap headline multiples: P/E 7.4 and P/B 0.8 at current price, supporting valuation resilience if earnings are reliable.
- Attractive cash return: reported dividend yield of 9.7% provides income while upside is limited.
- Solid reported profitability and returns: ROE 10.5% and ROA 7.0%, with gross margin of 23.1% indicating product-level pricing power.
- Forensic and earnings quality concerns: Beneish M-Score percentile in the 93rd and M-Score -0.0785 (above the -1.78 manipulation threshold) indicate elevated manipulation risk.
- Very low earnings-quality sub-scores (cash conversion 0/100, receivables 0/100) suggest reported profits may not convert to cash.
- Illiquidity and concentrated ownership (largest holder 20.33%, insiders >30% combined) increase execution risk and can amplify adverse moves; average volume ~367 shares two-week average.
- Model confidence is very_low and sanity flags include manipulation_risk, limiting reliance on intrinsic valuation; revenue is down (VND 171.3 bn in 2025 vs VND 190.0 bn in 2024).
Sector Context
CPC sits in the cyclical Hóa chất sector where earnings and multiples are sensitive to commodity cycles and end-market demand. Sector peers (385 companies) show a median implied upside of 5.6%, placing CPC below the peer median on our models. Several peers show stronger upside and higher confidence (examples: CST, KVC, NBC each with ~40.3% implied upside and medium confidence).
Regulatory context for Vietnamese chemical firms includes strict product registration, environmental and safety compliance costs, and exposure to SBV macro policies (credit availability). For small, lightly traded names, VAS accounting differences and potential off-balance-sheet items can further cloud comparability with peers; CPCs accounting flags make peer multiple differentials harder to justify without clearer cash conversion evidence.
Risk Factors
- Accounting/manipulation risk: Beneish M-Score signals and a low earnings quality score (7.9/100) raise the risk that reported earnings are overstated or not cash-backed.
- Cash conversion and receivables concentration: sub-scores of 0/100 for cash conversion and receivables suggest working capital volatility that could pressure liquidity.
- Illiquidity and concentrated ownership: average volume ~367 shares and top holder at 20.33% limits market liquidity and raises execution risk for larger traders.
- Revenue decline and cyclical exposure: Revenue fell from VND 190.0 bn (2024) to VND 171.3 bn (2025), exposing earnings to demand cycles.
- Model and data uncertainty: valuation model confidence flagged as very_low and sanity_flags include low_earnings_quality, reducing reliability of intrinsic estimates.
- Counterparty and regulatory risk in chemical distribution: product registration, environmental compliance and input price swings can compress margins.
- Foreign room: available foreign ownership capacity (~1,889,778.08 shares) is limited relative to float, restricting offshore demand.
Catalysts
- Release of audited cashflow detail demonstrating improved cash conversion and lower receivables would reduce forensic concerns.
- A clear recovery in revenue/EBITDA (stabilization after the 2025 decline) could re-rate the stock if coupled with better earnings quality.
- Corporate actions that increase free float or reduce insider concentration (share sales, listing of block trades) could improve liquidity and valuation.
- Dividend declarations or confirmation of sustainable payout policy given the high stated yield.
Forensic Assessment
Forensic signals are the primary concern. The Beneish M-Score is -0.0785, which is above the manipulation threshold (-1.78) and sits in the 93rd percentile versus peers, indicating elevated risk of aggressive accounting and a year-over-year change that is concerning. Earnings quality is very poor at 7.9/100, with cash-conversion and receivable sub-scores at 0/100, undermining confidence that reported net profit (VND 9.0 bn in 2025) is cash-backed. On the constructive side, an Altman Z-Score of 3.13 (reported as a positive signal) implies low bankruptcy risk. Overall, forensic flags materially lower conviction in headline earnings and the valuation derived from them.
Track Record
The model track record covers 12 years with a historical hit rate of 81.8% and an average realized upside of 50.9% when calls were correct. While the historical hit rate is strong, the current model confidence is very_low due to weak input quality and forensic flags, so past model performance should be weighted cautiously in this case.
Written by a language model on 2026-08-10 from this page’s own model outputs and financial statements, and may quote figures from that date. Descriptive analysis, not investment advice — no buy, sell or hold recommendation is given or implied.